Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Study of Sitravatinib + PD-(L)1 Checkpoint Inhibitor Regimens in Urothelial Carcinoma
Multiple Cancer Types
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
Bladder,
Urologic
II
Davis, Nancy
NCT03606174
VICCURO18175
